Biogen and Eisai are seeking approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease in Japan, the companies have announced. If approved, aducanumab will become the first therapy with the potential to slow the clinical decline seen in patients with Alzheimer’s. “The filing of the application is an important step in serving patients and their families as aducanumab may help reduce clinical decline and potentially maintain the ability to live an independent life for as…
You must be logged in to read/download the full post.
The post Biogen, Eisai Request Approval of Aducanumab for Alzheimer’s in Japan appeared first on BioNewsFeeds.